LOS ANGELES, June 22, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced an
agreement with Pure MHC, an Emergent Technologies portfolio
company, for development of a novel assay for quality control that
will be an important component of ImmunoCellular's ICT-107 phase 3
registrational clinical program in newly diagnosed glioblastoma,
anticipated to begin in the second half of 2015. Under the terms of
the agreement, Pure MHC will develop and validate a new assay
specifically created for ICT-107, a dendritic-cell based
immunotherapy targeting six antigens found on glioblastoma cells,
especially stem cells. The new assay will be used to validate
the quality and confirm the activity of ICT-107 and allow it to be
released for administration to patients in the phase 3 trial.
"The agreement with Pure MHC is another important milestone in
ImmunoCellular's progress toward the phase 3 registration trial for
ICT-107," said Andrew Gengos,
ImmunoCellular Chief Executive Officer. "Designing a new release
assay to support the specific requirements of the ICT-107
six-antigen complex requires special skill and expertise, and we
are confident in Pure MHC's ability to deliver a validated release
assay. We believe that the knowledge and know-how gained from
developing this assay can be applied to our other dendritic
cell-based immunotherapy programs, thus representing a meaningful
return on investment for our Company. We look forward to continuing
to advance toward beginning patient enrollment in the phase 3 trial
of ICT-107 in the late third quarter or early fourth quarter of
this year."
"Pure MHC has developed a suite of platform technologies in the
field of immuno-oncology including the use of TCRm mAb to validate
peptide vaccine delivery," said Tommy
Harlan, Pure MHC Chief Executive Officer. "Pure MHC
looks forward to using its patented TCRm potency assay to support
the release of ImmunoCellular's ICT-107 dendritic cell-based
immunotherapy for glioblastoma."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a phase 2 trial of its
lead product candidate, ICT-107, a dendritic cell-based
immunotherapy targeting multiple tumor-associated antigens on
glioblastoma stem cells. ImmunoCellular's pipeline also includes:
ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen
on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell
immunotherapy targeting antigens on ovarian cancer stem cells; and
the Stem-to-T-cell research program which engineers the patient's
hematopoietic stem cells to generate antigen-specific
cancer-killing T-cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular
Therapeutics
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
the risk that ICT-107 can be further successfully developed or
commercialized and the potential timing for the initiation of
registrational phase 3 study for this molecule. Additional risks
and uncertainties are described in IMUC's most recently filed
quarterly report on Form 10-Q and annual report on Form 10-K.
Except as permitted by law, IMUC undertakes no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
About Pure MHC
Pure MHC, LLC is a platform technology company under the
scientific leadership of William
Hildebrand, PhD, with expertise in disease-specific target
identification, and validation as well as immunotherapeutic drug
development for cancer, infectious, and autoimmune diseases as well
as allergy. Pure MHC identifies and leverages
the same disease targets for drug discovery that the
immune system naturally uses to identify foreign or
aberrant protein targets in cancerous, infected, or unhealthy
cells. Pure MHC was formed and is managed by Austin-based innovations solutions company,
Emergent Technologies, Inc. For more information please visit
www.puremhc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-establishes-agreement-with-pure-mhc-for-novel-quality-control-assay-for-ict-107-phase-3-registrational-trial-300101808.html
SOURCE ImmunoCellular Therapeutics, Ltd.